RECRUITING

A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to learn more about the challenges with breast cancer diagnosis in Tanzania and the support available to improve this process.

Official Title

A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania

Quick Facts

Study Start:2023-04-13
Study Completion:2026-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05438511

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Breast cancer survivor, patient advocate or key healthcare personnel
  2. * Key healthcare personnel are defined as hospital and laboratory leaders, pathologists, laboratory scientists and technicians, oncologists, nurses, and surgeons, with:
  3. * \>12 months of employment at the affiliated institution
  4. * Administrative or clinical involvement in the delivery of breast cancer care services.
  5. * Age 18 years and above
  6. * Permanent residents or citizens of Tanzania
  7. * Participant and/or LAR willing and able to consent
  8. * Fluent in Swahili and/or English by self-report
  1. * Key stakeholder not residing at their particular institutions during data collection will be excluded.
  2. * Age 18 years and above
  3. * Permanent residents or citizens of Tanzania
  4. * Received breast cancer diagnosis

Contacts and Locations

Study Contact

Diana Ng, MD
CONTACT
212-639-7209
NgD2@mskcc.org
T. Peter Kingham, MD
CONTACT
212-639-5260
kinghamP@mskcc.org

Principal Investigator

Diana Ng, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Diana Ng, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-13
Study Completion Date2026-04

Study Record Updates

Study Start Date2023-04-13
Study Completion Date2026-04

Terms related to this study

Keywords Provided by Researchers

  • breast cancer hormone receptor testing
  • breast cancer testing
  • GeneXpert STRAT4
  • Memorial Sloan Kettering Cancer Center
  • 21-480

Additional Relevant MeSH Terms

  • Breast Cancer